NCT02074839 2025-06-08Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationServierPhase 1 Recruiting291 enrolled 3 FDA
NCT04176393 2023-02-13A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 MutationCStone PharmaceuticalsPhase 1 Completed30 enrolled